Article
Oncology
Elzbieta Senkus, Suzette Delaloge, Susan M. Domchek, Pierfranco Conte, Seock-Ah Im, Binghe Xu, Anne Armstrong, Norikazu Masuda, Anitra Fielding, Mark Robson, Nadine Tung
Summary: In the primary analysis of the phase III OlympiAD trial, olaparib significantly extended the progression-free survival in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer compared to chemotherapy treatment. Subgroup analyses confirmed the consistent benefit of olaparib across various patient subgroups.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Oncology
Karen A. Gelmon, Peter A. Fasching, Fergus J. Couch, Judith Balmana, Suzette Delaloge, Intidhar Labidi-Galy, James Bennett, Susan McCutcheon, Graham Walker, Joyce O'Shaughnessy
Summary: The study evaluated the clinical effectiveness of olaparib in patients with gBRCAm, showing a significant increase in progression-free survival and consistent safety outcomes compared with previous findings.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Mark E. Robson, Seock-Ah Im, Elzbieta Senkus, Binghe Xu, Susan M. Domchek, Norikazu Masuda, Suzette Delaloge, Nadine Tung, Anne Armstrong, Mike Dymond, Anitra Fielding, Allison Allen, Pierfranco Conte
Summary: In the Phase III OlympiAD study, olaparib demonstrated a significant prolongation of progression-free survival for patients with germline BRCA-mutated metastatic breast cancer, especially in those receiving it as first-line treatment. The median overall survival for olaparib was 19.3 months, compared to 17.1 months for chemotherapy treatment of physician's choice. These results suggest a potential long-term survival benefit with olaparib.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Pharmacology & Pharmacy
Na Li, Huanrui Zheng, Yanlei Huang, Bin Zheng, Hongfu Cai, Maobai Liu
Summary: The study found that olaparib was more cost-effective than placebo for maintenance therapy in metastatic pancreatic cancer in both China and the United States.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Oncology
Stefania Morganti, Brittany L. Bychkovsky, Philip D. Poorvu, Ana C. Garrido-Castro, Anna Weiss, Caroline C. Block, Ann H. Partridge, Giuseppe Curigliano, Nadine M. Tung, Nancy U. Lin, Judy E. Garber, Sara M. Tolaney, Filipa Lynce
Summary: In the OlympiA study, adjuvant olaparib was found to significantly improve survival in BRCA1/2 mutation carriers with high-risk, HER2-negative early breast cancer. However, integrating olaparib with other available agents in the post(neo)adjuvant setting poses challenges due to lack of data on selection, sequencing, and combination strategies. Additionally, identifying additional patients who could benefit from olaparib beyond the current criteria remains unclear. This article reviews existing data to aid treatment decisions for high-risk, germline BRCA1/2 mutation carriers with early breast cancer.
Article
Oncology
Fatma Nihan Akkoc Mustafayev, Mihir Amitabh Shukla, Amanda Lanier, Denai R. Milton, Angelica M. Gutierrez, Stephen K. Gruschkus, John E. Lewis, Rashmi K. Murthy, Banu K. Arun
Summary: BRCA1/2 mutations occurred in 6.6% of patients with human epidermal growth factor receptor 2 (HER2/neu)-positive breast cancer. However, BRCA mutation status did not affect survival outcomes in patients who had HER2/neu-positive breast cancer.
Article
Oncology
Hedy L. Kindler, Hyun Kyoo Yoo, Robert Hettle, Karen Y. Y. Cui, Seongjung Joo, Gershon Y. Locker, Talia Golan
Summary: The POLO study showed that maintenance treatment with olaparib significantly improves progression-free survival and does not compromise health-related quality of life in patients with metastatic pancreatic cancer and a germline BRCA mutation. A post hoc analysis found that olaparib treatment is associated with a longer period of time without significant symptoms of disease progression or toxicity (TWiST), but no significant difference in quality-adjusted TWiST (Q-TWiST).
Article
Oncology
A. Viansone, B. Pellegrino, C. Omarini, M. Pistelli, D. Boggiani, A. Sikokis, V. Uliana, D. Zanoni, C. Tommasi, B. Bortesi, F. Bonatti, F. Piacentini, L. Cortesi, R. Camisa, P. Sgargi, M. Michiara, A. Musolino
Summary: The study found that patients with HER2-positive breast cancer are more likely to have high histologic grade and proliferation rate among BRCA mutation carriers. The co-occurrence of BRCA mutations and HER2-positive status is associated with worse survival outcomes.
Article
Oncology
Binghe Xu, Tao Sun, Yanxia Shi, Jiuwei Cui, Yongmei Yin, Quchang Ouyang, Qiang Liu, Qingyuan Zhang, Yiding Chen, Shouman Wang, Xiaojia Wang, Zhongsheng Tong, Yahua Zhong, Jiayu Wang, Min Yan, Xi Yan, Chuan Wang, Jifeng Feng, Xiuli Wang, Gang Hu, Ying Cheng, Ruimin Ge, Zhaoyin Zhu, Wa Zhang, Zhimin Shao
Summary: This study conducted in China showed that Pamiparib had promising efficacy and an acceptable safety profile in patients with locally advanced and metastatic HER2-negative breast cancer with deleterious or suspected deleterious gBRCA1/2 mutations.
BREAST CANCER RESEARCH AND TREATMENT
(2022)
Article
Oncology
Hedy L. Kindler, Pascal Hammel, Michele Reni, Eric Van Cutsem, Teresa Macarulla, Michael J. Hall, Joon Oh Park, Daniel Hochhauser, Dirk Arnold, Do-Youn Oh, Anke Reinacher-Schick, Giampaolo Tortora, Hana Alguel, Eileen M. O'Reilly, Sonal Bordia, David McGuinness, Karen Cui, Gershon Y. Locker, Talia Golan
Summary: The POLO study demonstrated that active olaparib maintenance therapy did not show a statistically significant overall survival benefit for patients with metastatic pancreatic adenocarcinoma, but did show significant benefits in other secondary endpoints.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Review
Health Care Sciences & Services
Charles McCrea, Robert Hettle, Poonam Gulati, Ankush Taneja, Preety Rajora
Summary: The study compared the efficacy and safety of olaparib and talazoparib in treating breast cancer, with no significant difference in efficacy but differences in specific adverse events noted between the two.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH
(2021)
Article
Oncology
Milind Javle, Einat Shacham-Shmueli, Lianchun Xiao, Gauri Varadhachary, Naama Halpern, David Fogelman, Ben Boursi, Syeda Uruba, Ofer Margalit, Robert A. Wolff, Talia Golan
Summary: This study aimed to investigate the therapeutic effectiveness of the PARP inhibitor olaparib for patients with pancreatic cancer with BRCAness. The results of two phase 2 nonrandomized clinical trials showed that olaparib demonstrated good tolerability and limited antitumor activity in patients with advanced, platinum-sensitive PDAC with DDR-GAs, suggesting a potential therapeutic opportunity for a subset of patients with PDAC.
Article
Oncology
Chao Wu, Mengjiao Fan, Yi Hu
Summary: In this study, we report a case of metastatic lung adenocarcinoma with BRCA2 mutation that responded well to olaparib, expanding the spectrum of BRCA-mutated cancers suitable for olaparib therapy.
Review
Oncology
Huijun Lei, Min Zhang, Luyao Zhang, Kari Hemminki, Xiao-jia Wang, Tianhui Chen
Summary: Carriers with BRCA1/2 germline pathogenic variants have a high risk of breast and ovarian cancers, among others. The prevalence and spectrum of germline BRCA mutations in the Chinese population show ethnic specificity. Next-generation sequencing panel is the common method for BRCA1/2 screening. It is recommended that all Chinese individuals diagnosed with breast, ovarian, pancreatic, or prostate cancers, as well as healthy family members, undergo BRCA1/2 gene testing to provide risk assessment and timely preventive measures.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Wei Chen, Wei Xia, Song Xue, Hang Huang, Qi Lin, Yi Liu, Tongtong Liu, Yiqun Zhang, Panwang Zhang, Jianfei Wang, Yining Yang, Baijun Dong, Zhixian Yu
Summary: Recent studies have shown that Chinese patients with prostate cancer (PCa) carrying BRCA1/2 germline mutations tend to have more aggressive cancer. The frequency of germline pathogenic mutations is higher in BRCA2 compared to BRCA1, and FOXA1, NCOR2, and TP53 somatic mutations are associated with higher BRCA1/2 germline pathogenic mutations. This study provides important reference data for the precise diagnosis and treatment of Chinese PCa patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Yutaka Yamamoto, Hiroji Iwata, Naruto Taira, Norikazu Masuda, Masato Takahashi, Tetsuhiro Yoshinami, Takayuki Ueno, Tatsuya Toyama, Takashi Yamanaka, Toshimi Takano, Masahiro Kashiwaba, Koichiro Tsugawa, Yoshie Hasegawa, Kenji Tamura, Hiroshi Tada, Fumikata Hara, Tomomi Fujisawa, Naoki Niikura, Shigehira Saji, Satoshi Morita, Masakazu Toi, Shinji Ohno
Summary: This study aimed to examine the efficacy of pertuzumab retreatment for HER2-positive locally advanced or metastatic breast cancer. The results showed that adding pertuzumab significantly improved progression-free survival in all patients and showed a trend towards better overall survival and duration of response.
Article
Oncology
Haruru Kotani, Norikazu Masuda, Toshinari Yamashita, Yoichi Naito, Tetsuhiko Taira, Kenichi Inoue, Masato Takahashi, Kan Yonemori, Shigeyuki Toyoizumi, Yuko Mori, Takashi Nagasawa, Natsuki Hori, Hiroji Iwata
Summary: This study evaluated the efficacy and safety of talazoparib in Japanese patients with gBRCA1/2-mutated advanced breast cancer. The results showed that talazoparib monotherapy resulted in clinically meaningful treatment response in patients with gBRCA mutations.
Article
Oncology
Jung Hwan Ji, Soong June Bae, Seul-Gi Kim, Min Hwan Kim, Gun-Min Kim, Joohyuk Sohn, Joon Jeong, Jee Hung Kim, Sung Gwe Ahn
Summary: This study investigated the impact of different doses of carboplatin on pathologic complete response rate, grade 3/4 anaemia occurrence, and transfusion rate in patients treated with neoadjuvant TCHP. The results showed that carboplatin at AUC5 has comparable cytotoxic effects to carboplatin at AUC6 and is associated with fewer complications related to anaemia in HER2+ breast cancer patients.
Article
Oncology
Hee Kyung Ahn, Sung Hoon Sim, Koung Jin Suh, Min Hwan Kim, Jae Ho Jeong, Ji-Yeon Kim, Dae-Won Lee, Jin-Hee Ahn, Heejung Chae, Kyung-Hun Lee, Jee Hyun Kim, Keun Seok Lee, Joo Hyuk Sohn, Yoon-La Choi, Seock-Ah Im, Kyung Hae Jung, Yeon Hee Park
Summary: This study aimed to investigate the feasibility and efficacy of neoadjuvant treatment with atezolizumab, docetaxel, trastuzumab, and pertuzumab in patients with ERBB2-positive early breast cancer. The results showed that this treatment regimen had an acceptable pCR rate and modest toxic effects, highlighting the importance of further research on the use of this combination in early breast cancer.
Article
Oncology
Sung Hoon Sim, Jeong Eun Kim, Min Hwan Kim, Yeon Hee Park, Jee Hyun Kim, Koung Jin Suh, Su-Jin Koh, Kyong Hwa Park, Myoung Joo Kang, Mi Sun Ahn, Kyoung Eun Lee, Hee -Jun Kim, Hee Kyung Ahn, Han Jo Kim, Keon Uk Park, Jae Ho Byun, Jin Hyun Park, Gyeong-Won Lee, Keun Seok Lee, Joohyuk Sohn, Kyung Hae Jung, In Hae Park
Summary: This study investigated the effectiveness and safety of a trastuzumab biosimilar, Herzuma, combined with treatment of physician's choice in patients with HER2+ metastatic breast cancer who had failed at least two HER2 directed chemotherapies.
Article
Nanoscience & Nanotechnology
Yoshimasa Kosaka, Toshiaki Saeki, Toshimi Takano, Tomoyuki Aruga, Toshinari Yamashita, Norikazu Masuda, Yukio Koibuchi, Akihiko Osaki, Junichiro Watanabe, Ryu Suzuki
Summary: This study compared the efficacy and safety of NK105 and paclitaxel in the treatment of advanced recurrent breast cancer at equivalent dose levels. The results showed similar efficacy between the two groups, but a delayed onset of peripheral sensory neuropathy in the NK105 group.
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2022)
Article
Medicine, General & Internal
Seung-Ah Lee, Ji-Man Hong, Jung Hwan Lee, Young-Chul Choi, Hyung Jun Park
Summary: Bethlem myopathy, a type of collagens VI-related muscular dystrophies, was studied to analyze its gene expression profiles in skeletal muscle. RNA-sequencing of samples from patients and controls identified 187 significantly differentially expressed transcripts, with implications on ECM and wound healing processes. This transcriptome profiling provides new insights into the path mechanism of Bethlem myopathy associated with non-protein coding RNAs.
Article
Multidisciplinary Sciences
Seung-Ah Lee, Hyun Joon Lee, Bum Chun Suh, Ha Young Shin, Seung Woo Kim, Byeol-A Yoon, Young-Chul Choi, Hyung Jun Park
Summary: This study measured anti-NT5c1A antibodies in 103 patients with inflammatory myopathies and found that 13 (12.6%) patients were seropositive for the antibody. Among these, inclusion body myositis (IBM) patients had the highest frequency of anti-NT5c1A antibody positivity (40%), followed by dermatomyositis (15.4%), immune-mediated necrotizing myopathy (7.1%), and polymyositis (2.4%). There were no significant clinical differences between anti-NT5c1A antibody-seropositive and seronegative IBM groups.
Article
Oncology
Masaya Hattori, Norikazu Masuda, Toshimi Takano, Koichiro Tsugawa, Kenichi Inoue, Koji Matsumoto, Takashi Ishikawa, Mitsuya Itoh, Hiroyuki Yasojima, Yuko Tanabe, Keiko Yamamoto, Masato Suzuki, Wilbur Pan, Javier Cortes, Hiroji Iwata
Summary: In the KEYNOTE-355 trial, pembrolizumab plus chemotherapy showed improved progression-free survival (PFS) and overall survival (OS) compared to placebo plus chemotherapy in previously untreated patients with locally recurrent inoperable or metastatic triple-negative breast cancer. The study included Japanese patients, and the results were consistent with the global population. The combination of pembrolizumab and chemotherapy demonstrated manageable toxicity and supported its use in this setting.
Article
Oncology
Toshimi Takano, Mitsuya Ito, Takayuki Kadoya, Tomofumi Osako, Tomoyuki Aruga, Norikazu Masuda, Toshiko Miyaki, Naoki Niikura, Daisuke Shimizu, Yuichi Yokoyama, Manabu Watanabe, Masato Tomomitsu, Kenjiro Aogi
Summary: This study investigated the efficacy and safety of MD-110 in early-stage breast cancer patients receiving neoadjuvant or adjuvant myelosuppressive chemotherapy. The results showed that MD-110 was effective in reducing chemotherapy-induced neutropenia without additional safety concerns.
Article
Oncology
Misato Masuyama, Norikazu Masuda, Hidetoshi Kawaguchi, Yutaka Yamamoto, Shigehira Saji, Takahiro Nakayama, Kenjiro Aogi, Keisei Anan, Shoichiro Ohtani, Nobuaki Sato, Toshimi Takano, Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Masaya Hattori, Tomomi Fujisawa, Satoshi Morita, Miki Yamaguchi, Toshinari Yamashita, Daisuke Yotsumoto, Masakazu Toi, Shinji Ohno
Summary: The role of endocrine therapy in postmenopausal patients with ER-positive HER2-positive AMBC is unclear. The Safari study analyzed data from 94 patients and found that F500 therapy as first- or second-line treatment resulted in longer TTF. Furthermore, patients with TTC ≥ 3 years had prolonged OS, suggesting that this value could be used as a cut-off for predicting clinical outcomes.
Article
Health Care Sciences & Services
Si Won Lee, Jung Hye Kwon, Seung-hoon Beom, Sang Joon Shin, Hyo Song Kim, Sun Young Rha, Minkyu Jung, Joo Hyuk Sohn, Joong-Bae Ahn, Hyun Cheol Chung, Gun Min Kim, Hye Ryun Kim, Beodeul Kang, Youn Jung Hu, Hye Jin Choi
Summary: This study evaluated the first-year outcomes of patients admitted to an acute palliative care unit (APCU) at a tertiary hospital in Korea. The results showed that during their stay in the APCU, the overall symptoms of inpatients were reduced.
PALLIATIVE MEDICINE REPORTS
(2023)
Article
Oncology
Chang Gon Kim, Min Hwan Kim, Jee Hung Kim, Seul-Gi Kim, Gun Min Kim, Tae Yeong Kim, Won-Ji Ryu, Jee Ye Kim, Hyung Seok Park, Seho Park, Young Up Cho, Byeong Woo Park, Seung Il Kim, Joon Jeong, Joohyuk Sohn
Summary: This study analyzed data from postmenopausal women with HR-positive, HER2-negative ABC who were treated with CDK4/6 inhibitors and found that on-treatment dNLR predicted progression-free survival (PFS). Flow cytometry analysis revealed potential systemic immune responses induced by CDK4/6 inhibitors, including prevention of T cell exhaustion and reduction of myeloid-derived suppressor cell frequency.
BREAST CANCER RESEARCH
(2023)
Article
Oncology
Se Hyun Kim, Seock-Ah Im, Koung Jin Suh, Kyung-Hun Lee, Min Hwan Kim, Joohyuk Sohn, Yeon Hee Park, Ji-Yeon Kim, Jae Ho Jeong, Kyoung Eun Lee, In Sil Choi, Kyong Hwa Park, Hee-Jun Kim, Eun Kyung Cho, So Yeon Park, Milim Kim, Jee Hyun Kim
Summary: This study evaluated the efficacy and safety of nivolumab and eribulin combination therapy for metastatic breast cancer in Asian populations. The results showed that this combination therapy had relatively good efficacy and tolerable safety in patients with hormone receptor-positive/HER2-negative and triple-negative breast cancer.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Clinical Neurology
Hee Jo Han, Seung-Ah Lee, Young-Chul Choi, Michael R. Rose, Hyung Jun Park
Summary: The purpose of this study was to translate and validate the Korean version of INQoL in Korean patients with neuromuscular diseases. The results showed that the Korean INQoL is a reliable and validated measurement tool for Korean patients with neuromuscular diseases.
JOURNAL OF CLINICAL NEUROLOGY
(2022)